Skip to main content
Premium Trial:

Request an Annual Quote

Massive Bio to Provide AI Analytics to Precision Cancer Consortium

NEW YORK – Massive Bio said Friday that it will provide artificial intelligence-powered analytics technology to the Precision Cancer Consortium (PCC) a year-old group of biopharmaceutical firms collaborating to increase access to genomic testing in oncology.

The New York-based bioinformatics company will incorporate clinical trial protocols from PCC members into its Synergy-AI registry to optimize the matching of patients to trials as well as to widen patient access to next-generation sequencing and precision interventions.

"With this partnership, we can streamline the process of clinical trial matching and reduce the burden on patients and healthcare systems," Massive Bio Founder and CEO Selin Kurnaz said in a statement.

"This collaboration has the potential to address a major challenge in precision oncology and improve patient outcomes," added Yinghui Zhou, PCC project lead and senior director of Bayer Translational Sciences Oncology. "By working together and utilizing a collection of genomics data from multiple sources centralized with the assistance of AI, we can create a valuable scientific resource and optimize the efficiency of clinical trial matching globally and scale."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.